Trimedyne/Bard submits 510(k) for Urolase BPH indication per FDA policy change.
This article was originally published in The Gray Sheet
Executive Summary
TRIMEDYNE/BARD UROLASE FOR BPH: 510(K) HAS BEEN SUBMITTED to FDA, Bard says. The submission was filed in the wake of a recent change in FDA policy that allows laser manufacturers to use 510(k)s with "limited confirmatory data" to seek clearance for labeling indications for the treatment of benign prostatic hyperplasia. Trimedyne's 510(k) is supported by data from an already pending premarket approval application, according to Bard.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.